Exelixis
EXEL
#2109
Rank
โ‚น632.25 B
Marketcap
โ‚น2,216
Share price
-1.53%
Change (1 day)
23.95%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : โ‚น54.81 B

According to Exelixis's latest financial reports the company's total liabilities are โ‚น54.81 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚น56.47 B17.06%
2022-12-31โ‚น48.24 B59.61%
2021-12-31โ‚น30.22 B60.34%
2020-12-31โ‚น18.85 B32.63%
2019-12-31โ‚น14.21 B51.56%
2018-12-31โ‚น9.37 B-60.34%
2017-12-31โ‚น23.64 B-31.29%
2016-12-31โ‚น34.41 B9.46%
2015-12-31โ‚น31.43 B13.39%
2014-12-31โ‚น27.72 B2.65%
2013-12-31โ‚น27.00 B16.15%
2012-12-31โ‚น23.25 B45.26%
2011-12-31โ‚น16.00 B-39.38%
2010-12-31โ‚น26.41 B11.8%
2009-12-31โ‚น23.62 B3.78%
2008-12-31โ‚น22.76 B76.74%
2007-12-31โ‚น12.87 B-4.6%
2006-12-31โ‚น13.49 B8.92%
2005-12-31โ‚น12.39 B30.94%
2004-12-31โ‚น9.46 B5.7%
2003-12-31โ‚น8.95 B14.43%
2002-12-31โ‚น7.82 B48.26%
2001-12-31โ‚น5.27 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น4.701 T 8,477.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น5.104 T 9,212.05%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น5.787 T 10,457.60%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.508 T 11,773.06%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.129 T 12,906.38%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น9.190 T 16,666.48%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น10.756 T 19,523.59%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.28 B-92.18%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.07 B-88.92%๐Ÿ‡บ๐Ÿ‡ธ USA